Morepen Labs Completes Phase 1 Capacity Expansion Ahead of Schedule

Morepen Laboratories Ltd has successfully completed the first phase of its manufacturing capacity expansion program ahead of schedule. This expansion increases the company's installed reactor capacity for API and CDMO from 535 KL to 614 KL. The enhanced capacity will support the scale-up of commercial CDMO supplies, bolster the existing API business, and accommodate future customer programs. This milestone is a key part of Morepen's strategy to build a scalable, globally compliant manufacturing platform focused on long-term customer partnerships and sustained growth in its API and CDMO segments.